SEKISUI XenoTech is a specialty global Contract Research Organization (CRO) specializing in ADME/DMPK/DDI testing on potential drug candidates. Utilized by top pharma, universities, biotech companies, and numerous other organizations, SEKISUI XenoTech provides the finest tools and resources to advance the development of effective, safe drugs.
As a drug metabolism and drug-drug interactions (DDI) experts, SEKISUI XenoTech boasts more than 25 years of supporting drug developers to evaluate their compounds for pharmacokinetic properties, including absorption, distribution, metabolism, and excretion (ADME) and drug-drug interaction (DDI) potential. Services span in vivo and in vitro contracted studies, and products such as cryoplateable hepatocytes and subcellular fractions are available to drug developers worldwide to ensure top quality test systems for their in-house assays.
Equipped with data from pharmacokinetic studies, drug developers can bring safe, effective therapeutics to market faster. Early in vitro data to develop a drug compound’s pharmacokinetic profile can support confident, informed, risk-based decision making early on in a compound’s development, potentially mitigating serious setbacks later in the pipeline. To learn more about how you can use in vitro and in vivo ADME/PK and DDI studies to bolster your drug compound’s chance of success, visit xenotech.com